PROMIS depression measures perform similarly to legacy measures relative to a structured diagnostic interview for depression in cancer patients
PROMIS depression measures perform similarly to legacy measures relative to a structured diagnostic interview for depression in cancer patients
复制标题
DOI：
10.1007/s11136-018-1803-x
复制
发表时间：
2018-05-01
影响因子：
3.5
通讯作者：
Carter, Gregory
中科院分区：
文献类型：
--
作者：
Clover, Kerrie;Lambert, Sylvie D.;Carter, Gregory
评估患者报告结局测量信息系统（PROMIS）抑郁测量相对于传统测量的收敛效度，以及肿瘤样本中抑郁结构化诊断访谈的标准效度。132名肿瘤/血液科门诊患者完成了PROMIS抑郁计算机自适应测试（PROMIS-D-CAT）和PROMIS抑郁简表（PROMIS-D-SF）沿着7项传统测量指标：贝克抑郁量表（BDI）、抑郁流行病学研究中心（CES-D）、抑郁、焦虑和压力量表;医院焦虑和抑郁量表;病人健康问卷;痛苦温度计和PSYCH-6。相关性、曲线下面积（AUC）和诊断准确性统计以结构化临床访谈作为金标准进行计算。两种PROMIS测量与所有传统测量在p <0.001（rho = 0.589-0.810）处相关，并且所有AUC（> 0.800）是可比的。在轻度抑郁的临界点为53时，PROMIS测量的灵敏度（PROMIS-D-CAT为0.83，PROMIS-D-SF为0.80）类似于或优于6/7具有高阴性预测值（> 90%）的传统测量。在60的中度抑郁的截止点处，PROMIS测量具有> 90%的特异性，类似于或优于所有传统测量，并且阳性预测值ae为0.50（类似于5/7的传统测量）JROMIS抑郁测量在癌症人群中的收敛有效性和标准有效性得到证实，尽管最佳截止点尚未建立。PROMIS指标比BDI-II和CES-D更简短，但在诊断准确性、降低应答负担或成本方面，与肿瘤患者中的其他传统抑郁指标相比，没有任何进步。
To assess the convergent validity of the Patient-Reported Outcomes Measurement Information System (PROMIS) depression measures relative to legacy measures and criterion validity against a structured diagnostic interview for depression in an oncology sample.132 oncology/haematology outpatients completed the PROMIS Depression Computer Adaptive Test (PROMIS-D-CAT) and PROMIS Depression Short Form (PROMIS-D-SF) along with seven legacy measures: Beck Depression Inventory (BDI); Centre for Epidemiological Studies Depression (CES-D); Depression, Anxiety and Stress Scale; Hospital Anxiety and Depression Scale; Patient Health Questionnaire; Distress Thermometer and PSYCH-6. Correlations, area under the curve (AUC) and diagnostic accuracy statistics were calculated with Structured Clinical Interview as the gold standard.Both PROMIS measures correlated with all legacy measures at p < .001 (rho = 0.589-0.810) and all AUCs (> 0.800) were comparable. At the cut-off points for mild depression of 53, the PROMIS measures had sensitivity (0.83 for PROMIS-D-CAT and 0.80 for PROMIS-D-SF) similar to or better than 6/7 legacy measures with high negative predictive value (> 90%). At cut-off points of 60 for moderate depression, PROMIS measures had specificity > 90%, similar to or better than all legacy measures and positive predictive value ae 0.50 (similar to 5/7 legacy measures).The convergent and criterion validity of the PROMIS depression measures in cancer populations was confirmed, although the optimal cut-off points are not established. PROMIS measures were briefer than BDI-II and CES-D but do not offer any advance in terms of diagnostic accuracy, reduced response burden or cost over other legacy measures of depression in oncology patients.